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Executive Summary 
 
 
 
Substance identification 
DOC (4-chloro-2,5-dimethoxyamfetamine) (IUPAC name: 1-(4-chloro-2,5-
dimethoxyphenyl)propan-2-amine) is the chloro analogue of DOB (4-bromo-2,5-
dimethoxyamfetamine) and DOM (2,5-dimethoxy-4-methylamfetamine) which are both listed in 
Schedule I of the Convention on Psychotropic Substances of 1971. Information obtained from 
seizures and collections suggests that it has been encountered in powdered and liquid form but 
that it is predominantly found in the form of LSD-like blotter papers.  
 
WHO Review History 
DOC has not been previously pre-reviewed or critically reviewed. 
 
Chemistry 
There is no specific information available about the routes of synthesis employed for seized DOC 
products circulating on the drug market but straightforward methods for its preparation exist 
without requiring access to precursors that are controlled internationally. The presence of an 
asymmetric carbon atom gives rise to the (R)- and (S)-enantiomer and it seems likely for DOC to be 
most commonly available in the racemic form. 
 
Ease of convertibility into controlled substances 
A conversion of DOC into another substance currently listed in any of the international drug 
conventions might be chemically feasible but specific information is not available. 
 
Similarity to known substances / Effects on the central nervous system 
DOC can be considered a classical (serotonergic) hallucinogen and its effects and potency are 
comparable to the hallucinogenic amfetamines DOB, DOM and DOI (4-iodo-2,5-
dimethoxyamfetamine) and to some extent similar to LSD, psilocybin, mescaline and N,N-
dimethyltryptamine.  
 
General pharmacology 
DOC is a potent 5-HT2A receptor agonist with high affinity, a key element in mediating 
hallucinogenic effects in humans. The available data available so far also indicates that it also binds 
with high affinity to and activates 5-HT2B/2C receptors. Self-experiments suggested DOC to be active 
in the 1.5–3.0 mg range with duration of effects estimated to range between 12–24 h. A long 
duration of effects is also shared by the other hallucinogenic amfetamines DOI, DOB and DOM. 
DOC is most commonly administered orally and/or sublingually when encountered in the form of 
blotters. The discriminative stimulus effects of DOC in the drug discrimination paradigm were 
similar to those of other hallucinogens DOM and N,N-dimethyltryptamine but not 
methamfetamine. Data collected from in vitro metabolism studies showed that DOC is 
transformed into the two O-demethylated (2- and 5-position) metabolites. The parent molecule is 
the preferred analytical target in clinical casework.   
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Toxicology 
Information could not be identified. 
 
Adverse reactions in humans 
The total number of cases reported in the scientific literature is very small and the detection of 
other drugs in published cases has also been reported. Clinical features associated with DOC 
intoxication included agitation, aggressive behaviour, hallucinations, tachycardia, rhabdomyolysis, 
seizures, and hyperthermia. In one case, some clinical features were observed to persist for up to 
33 h.  
 
Dependence potential 
Dependence potential in humans or animals has not been demonstrated. 
 
Abuse potential 
Studies specifically linked to DOC could not be identified. 
 
Therapeutic applications / usefulness 
DOC is not known to have any therapeutic uses.  
 
Listing on WHO Model List of Essential Medicines 
DOC is not listed.  
 
Marketing authorizations 
DOC is not known to have any marketing authorisations. 
 
Industrial use 
DOC is not known to have any agricultural, industrial or cosmetic uses. 
 
Non-medical use 
The mode of use may involve the combinational use (intentionally or unintentionally) of other 
drugs and users may be unaware of the exact dose or compound being ingested (by whatever 
route). Household or subpopulation surveys that specifically probe for prevalence of DOC could 
not be identified. Use of DOC is presumably limited to people who use hallucinogenic drugs in 
recreational settings (e.g. home environments, outdoors, discotheques/nightclubs and outdoor 
music festivals) rather than the general population.  
 
Nature and magnitude of public health problems 
The information currently available suggests that DOC is most commonly found in the form of 
blotter papers and that it has also been misrepresented as LSD, which adds to health risks to 
people who use these substances where information about the identity and/or the dose are 
unavailable. Some Internet retailers also offer DOC for sale as a research chemical. Information 
from acute intoxications suggests that some people have obtained access to the powdered form 
which can increase the risk of overdose and untoward effects.   
 
Licit production, consumption, and international trade 
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DOC is available as standard reference material and produced for scientific research by 
commercial suppliers. Other uses could not be identified. 
 
Illicit manufacture and traffic 
DOC has been formally notified in Europe in 2004 but its first published synthesis dates back to 
1973. In Europe, DOC was encountered in seizures and collected specimens in several countries 
and notified between 2004–2016. The majority of notifications described the detection of DOC in 
blotters although powders and liquid samples were also reported. In the period between 2006 and 
2009, a number of DOC identifications obtained from seizures (mostly blotters but also some 
powdered and liquid material) have been published in the forensic literature the United States of 
America. According to UNODC, a total number of 77 countries have so far reported the detection 
of DOC. 
 
Current international controls and their impact 
DOC is not controlled under the 1961, 1971 or 1988 United Nations Conventions. 
 
Current and past national controls 
DOC is controlled in some UN Member States.  
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1.  Substance identification  
A. International Nonproprietary Name (INN) 
 Not available. 
B. Chemical Abstract Service (CAS) Registry Number 
42203-77-0 (HCl salt)  
123431-31-2 (freebase)  
53626-23-6 ((R)-isomer HCl salt)  
53626-24-7 ((S)-isomer HCl salt) 
773790-50-4 ((R)-isomer freebase)  
756418-21-0 ((S)-isomer freebase) 
1419924-18-7 (1,2,3,4,5,6-13C freebase)  
1794827-31-8 (2,5-(trideuteromethoxy) HCl salt)  
1795121-92-4 (2,5-(trideuteromethoxy) freebase) 
C. Other Chemical Names 
4-Chloro-2,5-dimethoxyamfetamine 
2,5-Dimethoxy-4-chloroamfetamine 
1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine  
1-(4-Chloro-2,5-dimethoxyphenyl)-2-propanamine 
2-(4-Chloro-2,5-dimethoxy-phenyl)-1-methyl-ethylamine  
4-Chloro-2,5-dimethoxyphenylisopropylamine 
D. Trade Names 
Not available. 
E. Street Names 
DOC  
3C-C  
4-Cl-2,5-DMA 
4-Chloro-2,5-DMA 
 
F. Physical Appearance 
DOC HCl is a white, odorless, and crystalline solid. 
G. WHO Review History 
DOC has not been previously pre-reviewed or critically reviewed. A direct critical 
review is proposed based on information brought to WHO’s attention that DOC 
clandestinely manufactured, of especially serious risk to public health and society, 
and of no recognized therapeutic use by any party. Preliminary data collected from 
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literature and different countries indicated that this substance may cause 
substantial harm and that it has no medical use. 
2. Chemistry 
A. Chemical Name 
IUPAC Name: 1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine 
CA Index Name: 4-Chloro-2,5-dimethoxy-α-methyl-benzeneethanamine   
B. Chemical Structure 
Free base: 
 
 
 
Molecular Formula: C11H16ClNO2 
Molecular Weight: 229.70g/mol 
C. Stereoisomers 
The presence of an asymmetric carbon atom in the α-position (asterisk above) gives 
rise to the (R)- and (S)-enantiomer of DOC. On the street level, DOC is most likely 
available in the racemic form.  
D. Methods and Ease of Illicit Manufacturing 
Information on the manufacturing of DOC seized or collected from the market is 
not available. Its preparation is straightforward and follows standard procedures 
using cheap reagents. One example follows the procedure outlined below which 
represents the first publication of DOC synthesis in 1973 (1). The procedure used in 
this approach begins with 2,5-dimethoxybenzaldehyde (A) followed by the Henry 
reaction to give the nitropropene intermediate (B) and reduction to 2,5-
dimethoxyamfetamine (DMA) (C). Protection of the amine leads to N-acetyl-DMA 
(D) that in turn is converted to the nitro analogue (E). The reduced 4-amino-DMA 
(F) undergoes a Sandmeyer reaction that yields the 4-chloro analogue (G). 
Deprotection releases the desired DOC product (H) in the racemic form (1). Other 
examples can be found in Annex 2. 
 
NH2O
OCl
*
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Reagents and conditions: (i) NH4Ac, nitroethane, AcOH; 100 °C, 3 h (ii) LiAlH4, Et2O, reflux, 20 h; (iii) 
Ac2O, NaAc, H2O, shaken until exothermic reaction ceased; (iv) HNO3, NaNO2, AcOH, H2O, rt, 4 h, 
then cooled; (v) Pd/C, H2, EtOH, rt, 3 days; (vi) HCl, H2O, NaNO2, CuCl; 0 °C–rt, then 70 °C and cooled 
(vii) NaOH, H2O, ethylene glycol, reflux, 15 h (1). 
E. Chemical Properties 
Melting point 
HCl: 193–194.5 °C (EtOH/Et2O) (1)  
HCl: 187–188 °C (acetone/EtOH) (2)  
HCl: 188–192 °C (EtOH/Et2O) (3) 
Freebase: 95–102 °C (EtOH/Et2O) (3) 
HCl: 194.6 °C (4) 
HCl (S)-Isomer: 198 °C (acetone/EtOH) (2)  
HCl (R)-Isomer: 195 °C (acetone/EtOH) (2)  
 
Boiling point 
Information could not be identified. 
 
Solubility 
Phosphate-buffered saline (pH 7.2) approximately 5 mg/mL (HCl) (5, 6); ~5 mg/mL 
in ethanol & DMSO and ~10 mg/mL in N,N-dimethylformamide (6). 
F. Identification and Analysis  
Data and analytical methodologies that facilitate the identification of DOC in various 
sample matrices are available (Annex 2). Analytical reference standards are 
accessible to assist with the implementation of routine methods of analysis 
associated with forensic and clinical investigations. Analysis of biological specimen 
might require the implementation of sensitive techniques in cases where low 
concentrations are involved due to the potency of this substance. Typically, the 
parent molecule is used as the analytical target and it has been observed that 
various immunoanalysis assays developed for detecting amfetamine and 
methamfetamine-type drugs might not be able to generate a positive finding for 
DOC (7-12) due to lack of sufficient cross-reactivity (exception: 33% in one 
particular amfetamine test kit (13)), thus, potentially leading to false negative 
findings when relying on such routine methods alone. It is most likely that collected 
and seized material will represent the racemic mixture rather than a specific 
O
O
H
O
O
O
NO2 O
O
NH2 O
O
H
N
O
O
O
H
N
O
O2N
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H2N
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enantiomer. The differentiation between the two enantiomers might present 
challenges in routine forensic laboratories unless more specific approaches are 
employed to facilitate chiral analysis. 
3. Ease of Convertibility Into Controlled Substances 
No information could be identified. Although it appears that a dehalogenation of 
DOC specifically has not been published, a variety of reductive dehalogenation 
methods exist that might be able to facilitate the removal for the chloro substituent 
(14, 15). Whether or not the amine would have to be protected for such a reaction 
has not been investigated. This dehalogenated intermediate (i.e. 2,5-
dimethoxyamfetamine, intermediate C (DMA), Section D) might then be available 
for bromination to give DOB (2, 16). The dehalogenation of DOC to DMA however 
would already constitute a conversion to a controlled substance since it is also 
listed in Schedule I of the 1971 UN Convention on Psychotropic Substances. A 
conversion of DOC to DOM has also not been investigated but examples exist that 
describe a bromine to methyl conversion (17). The methylation would however 
require N-protection. Overall, it might not be practical to consider a conversion into 
another controlled substance such as DMA, DOB or DOM given that these 
substances can be prepared quite easily using cheap reagents.  
4. General Pharmacology 
A. Routes of administration and dosage 
DOC is most commonly administered orally and/or sublingually when encountered 
in the form of paper blotters. A typical dose range to induce hallucinogenic effects 
has been estimated at 1.5–3.0 mg (18-20). Initial self-experiments documented by 
Shulgin in the early to mid-1970s suggested that DOC was inactive at 0.4 mg and 
below (21). In the United States of America, DOC has also been seized in the 
powdered and liquid form (22). The (R)-enantiomer of the hallucinogenic analogues 
DOM, DOB, and DOI have been shown to be more potent than the (S)-form and the 
racemate (18) but whether this extends to DOC remains to be confirmed.  
B. Pharmacokinetics 
In humans, hallucinogenic and other psychoactive effects have been reported to 
last between 12–24 h (18) and it is conceivable that further after effects might be 
experienced (depending on dose) beyond that time point. The analysis of rat urine 
(male Wistar) by gas chromatography mass spectrometry following administration 
by gastric incubation revealed the detection of the two O-demethylated (2- and 5-
position) metabolites that also underwent conjugation to glucuronides or sulfates 
(23). This main metabolic step was found to be catalysed by CYP2D6 in an in vitro 
assay that employed baculovirus-infected insect cell microsomes. Furthermore, 
DOC was found to function as a non-mechanism-based competitive CYP2D6 
inhibitor (24).  
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C. Pharmacodynamics 
The number of detailed pharmacological studies associated with DOC is 
comparatively limited. However, the available evidence suggest that it shares the 
pharmacological key features also observed with other classical (serotonergic) 
hallucinogenic analogues such as DOI, DOM, and DOB (18, 25, 26). DOC acts as a 5-
HT2A  receptor agonist with high affinity (Table 1), a key element in mediating the 
hallucinogenic effects in humans (27-30). The iodo analog (R)-DOI has emerged as a 
potent anti-inflammatory agent mediated by 5-HT2A activity (31) but whether this 
extends to closely related analogues such as DOC remains to be investigated. (R)-
DOI is also widely used as a radioligand for studies involving 5-HT2 receptor 
subtypes. 
  
  
Table 1. DOC in vitro data a Reference 
 
Binding to 5-HT2 receptors b 
 
DOC (Ki = 218 nM), DOB (Ki = 41 nM), DOI (Ki = 19 nM), DOM (Ki = 
100 nM) 
(32, 33) 
 
Binding to h5-HT2A/2B/2c receptors c 
 
h5-HT2A: DOC (Ki = 1.4 nM), DOB (Ki = 0.6 nM), DOI (Ki = 0.7 nM) 
h5-HT2B: DOC (Ki = 31.8 nM), DOB (Ki = 26.9 nM), DOI (Ki = 20.0 nM) 
h5-HT2C: DOC (Ki = 2.0 nM), DOB (Ki = 1.3 nM), DOI (Ki = 2.4 nM) 
r5-HT2B: DOC (Ki = 26.8 nM), DOB (Ki = 21.8 nM), DOI (Ki = 26.6 nM) 
(34) 
 
Binding to h5-HT1A and D2 dopamine receptors d 
 
r5-HT1A: DOC (Ki = 4520 nM), DOB (Ki = 4280 nM), DOI (Ki = 3175 
nM) 
 
hD2: DOC (Ki >10,000 nM), DOB (Ki >10,000 nM), DOI (Ki >10,000 
nM) 
(35) 
 
Binding to h5-HT1A and 5-HT2A/2C receptors e 
 
h5-HT1A: DOC (Ki >9,200 nM), LSD (Ki = 2.5 nM) 
h5-HT2A: DOC (Ki = 4 nM), LSD (Ki = 0.47 nM) 
h5-HT2C: DOC (Ki = 3.57 nM), LSD (Ki = 3.22 nM) 
 
DOC did not bind to dopamine and serotonin transporters (HEK-
hDAT and HEK-hSERT cells) with Ki below 10,000 nM; Ki DOC at HEK-
hNET = 7,700 nM 
(36) 
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Functional activity f 
 
h5HT1A [35S]GTPγS binding: DOC (EC50 > 10,000 nM and minimal 
activity as 5-HT1A antagonist using inhibition of WAY-100,635 (5-HT1A 
antagonist); LSD (EC50 = 6.4 nM) 
 
h5HT2A [3H]arachidonic acid (AA) release: DOC (EC50 = 2.91 nM); LSD 
(EC50 = 1.01 nM) 
 
h5HT2A IP-1 formation: DOC (EC50 = 1.5 nM; Emax = 102.4%); LSD 
(EC50 = 0.264 nM; Emax = 80.3%) 
 
h5HT2C IP formation: DOC (EC50 = 14.6 nM; Emax = 97%); LSD (EC50 = 
1.14 nM; Emax = 74.6%) 
 
(36) 
a As of July 2019. 
 
b Radioligand [3H]ketanserin (antagonist) (Ki = 1.2 nM); rat frontal cortex.   
 
c Radioligand [3H]DOI for 5-HT2A/2C and [3H]5-HT for 5-HT2B; membranes for radioligand 
binding assays prepared from suspension-grown AV12 cells (Syrian hamster fibroblasts) 
stably transformed with human 5-HT2A, 5-HT2B, or 5-HT2C receptors. Cloned rat 5HT2B 
also used. 
 
d Radioligand [3H]8-OH-DPAT for 5-HT1A and [3H]N-methylspiperone for D2 receptor; rat 
5-HT1A expressed in CHO cells. 
 
e Radioligand [3H]8-OH-DPAT for 5-HT1A and [3H]DOI for 5-HT2A/2C; HEK-h5HT1A, HEK-
h5HT2A, HEK-h5HT2C.  
 
f h5HT1A [35S]GTPγS binding to G proteins using HEK-5Ht1A cells; dose-response curve 
with full agonist serotonin conducted to identify full and partial agonist compounds; 
[3H]arachidonic acid release using HEK-5-HT2A cells; inositol-1-phosphate (IP-1) 
accumulation. Activation of 5-HT2A receptors by measuring accumulation of inositol 
mono- phosphate using an IP-1 Elisa kit; stimulated IP-1 formation normalised to the 
maximal effect of serotonin (100%). 
 
Existing animal data (Table 2) indicate that the potency of DOC is comparable to DOB and 
DOI and that it fully substituted for the discriminative stimulus effects of DOM, LSD, and 
DMT (N,N-dimethyltryptamine, with the latter depending on the time point tested) (36).   
 
 
Table 2. DOC in vivo animal data a Reference 
 (1) 
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Assessment of potency in rats b 
 
DOC found to be equipotent with DOM and DOB in male rats (10 mg/kg, 
p.o.) to induce hypersalivation, papillary dilation, retraction of scrotum, loss 
of orientation reflexes, analgesia, hypomotility, and walking with a slinking 
gait 
 
Assessment of potency in rabbits (hyperthermia) c 
 
DOC (0.12 µmol/kg): 80 min to peak effect; mean rise in temp = 1.40 °C; 
integrated temp (0–240 min) = 250 °C; approx. dose for 1 °C rise = 0.053 
µmol/kg; potency rel. to DOM = 3.77 (a) and 3.91 (b) 
 
DOB (0.1 µmol/kg): 100 min to peak effect; mean rise in temp = 1.45 °C; 
integrated temp (0–240 min) = 240 °C; approx. dose for 1 °C rise = 0.049 
µmol/kg; potency rel. to DOM = 4.05 (a) and 3.01 (b) 
 
DOM (0.5 µmol/kg): 120 min to peak effect; mean rise in temp = 1.43 °C; 
integrated temp (0–240 min) = 271 °C; approx. dose for 1 °C rise = 0.2 
µmol/kg; potency rel. to DOM = 1.00 (a) and 1.00 (b) 
 
LSD was 33- and 31.7-times more potent than DOM; a dose of 0.0061 
µmol/kg produced a 1 °C rise 
 
Assessment of potency in cats (EEG) d 
 
DOC (between 0.24 and 0.48 µmol/kg, i.m.); pupils less than 25% dilated 
DOB (between 0.2 and 0.4 µmol/kg, i.m.); pupils less than 25% dilated 
DOM (between 1 and 2 µmol/kg, i.m.); pupils less than 25% dilated 
LSD (between 0.05 and 0.1 µmol/kg, i.m.); pupils less than 25% dilated 
 
(2) 
 
The relative potency in the hyperthermia model of rabbits was listed as 
1000 (LSD), 114 (DOC) and 123 for DOB 
(37) 
 
Locomotor activity in mice e 
 
Time- and dose-dependent depression of locomotor activity following 3 and 
10 mg/kg DOC occurred within 10 min following injection and 
lasted 30–80 min. DOC also produced stimulant effects 
 
(36) 
 
Stimulus generalisation in drug discrimination studies f 
 
DOC substituted for DOM-trained rats, e.g. close to 100% at 0.7 mg/kg (i.m) 
(32) 
 (36) 
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Stimulus generalisation in drug discrimination studies g 
 
At 15 min: DOC fully substituted for DOM (ED50 = 0.13 mg/kg) and LSD (ED50 
= 0.39 mg/kg). DOC produced 65 % DMT appropriate responding (1 mg/kg), 
and <50 % drug-appropriate responding in MDMA- and methamfetamine-
trained rats. Response rate decreased following 2.5 mg/kg DOC. Rats failed 
to respond, and decreased muscle tone was observed in 12/24 rats. 
 
At 60 min: DOC fully substituted for DMT (ED50 = 0.61 mg/kg), DOM (ED50 = 
0.26), and LSD (ED50 = 0.23). In MDMA-trained rats, DOC produced 60% 
drug-appropriate responding (1 mg/kg), and none for methamfetamine at 
any dose. Doses of 1 mg/kg and higher decreased the response rates in rats. 
Substantial rate suppression and failure to complete the first fixed ratio 
were observed following 2.5 mg/kg DOC in MDMA-trained rats (4/6 rats) 
and 5 mg/kg in methamfetamine-trained rats (5/6 rats). 
 
Open field test. Compounds showing LSD-like effects h 
 
DOC (0.75 µmol/kg), DOB (0.064 µmol/kg), LSD (0.11 µmol/kg) 
 
(2) 
 
Conditioned place preference (CPP) i 
 
Mice conditioned with DOC (0.3 and 0.5 mg/kg) exhibited significantly 
increased place preference, when comparing the time spent in the drug 
paired compartment between the pre- and post-conditioning phases. DOC 
was stated to show aversive effects in the CPP at higher doses though it was 
unclear whether other reasons might have accounted for a reduced CPP at 
higher doses compared to intermediate doses.  
 
Self-administration in rats j 
 
Number of infusions and active lever presses for DOC (0.01 mg/(kg/infusion) 
not significantly different compared to the vehicle-treated group. The 
number of active lever presses (same dose) did also not increase 
significantly when assessing days 1–7 individually. However, an assessment 
of mean numbers of infusions and lever presses (during days 5–7) was 
considered significant without further details.   
 
(38) 
a As of July 2019. 
 
b DOM: 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine; DOB: 1-(4-bromo-2,5-
dimethoxyphenyl)propan-2-amine.  
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c Measurement of rectal temperature in Old English rabbits; potency expressed relative to 
DOM (a. max increase in temperature at particular does level, b: integrated area under 
time curve; approximate dose for 1 °C rise in temp also determined for comparison with 
DOM). Three different doses were tested per drug but results of only one test dose given 
in table above. Drugs were administered into rabbits by injection into a marginal ear vein. 
 
d Electrodes implanted in cats over lateral and suprasylvian gyri of cerebral cortex; drugs 
administered intramuscularly; when drugs produced hypersynchronous 4–6 Hz activity in 
EEG, an auditory stimulus of 1000 Hz 80 dB was presented; this stimulus elicited a standard 
behavioural response: cats opened eyes wide and raised or turned head toward source of 
sound; this standard behavioral response was accompanied by full synchronization (low 
amplitude, high frequency activity) in the EEG. At certain levels the 4–6 Hz activity 
reappeared after stimulus was switched off (“phasic” EEG response). Dose required to 
elicit phasic EEG response between the bursts of hypersynchronous 4–6 Hz  activity was 
determined. 
 
e Separate groups of 8 male Sprague-Dawley rats (0.1, 0.3, 1, 3, and 10mg/kg, i.p.). 
Horizontal activity (interruption of photocell beams) measured for 8 h within 10-min 
periods, beginning at 0800 (2 h after lights on).  
 
f No details given in this book chapter. 
 
g  Two-lever choice methodology, separate groups comprising 15 to 32 male Sprague-
Dawley rats trained to discriminate one of the five compounds from saline: 
methamfetamine (1 mg/kg), MDMA (1.5 mg/kg), LSD (0.1 mg/kg), DOM (0.5 mg/kg), and 
DMT (5 mg/kg) (all i.p. admininistration). Food available under FR 10 schedule of 
reinforcement.  Compounds tested 15 min after i.p. injection; DOC was tested at two time 
points, 15 and 60 min, which corresponded with the peak depressant and peak stimulant 
locomotor activity effects. In contrast with training sessions, both levers active, such that 
ten consecutive responses on either lever led to reinforcement. 
 
h  Open-field apparatus with circular arena (dimeter 82 cm) illuminated by 4 x 150 W lamps 
with background white noise level of 88 dB. LSD injected 15 min before testing but all 
other test drugs administered subcutaneously to groups of eight rats 1.5–3 h before 
animals were placed in the open field for a 3 min test period. Rats scored according to the 
number of times they reared, preened, and defaecated, the number of faecal boluses 
passed, the number of floor squares traversed at the periphery, and, separately, the 
number of squares traversed in the central part of the field. Doses quoted are the lowest 
at which significant effects were detected.  
 
i  C57BL/6 mice (i.p. injections) of vehicle or either of three doses of DOC (0.1, 0.3, and 0.5 
mg/kg) after the procedures were confirmed with methamfetamine (1 mg/kg). Unbiased 
method was used.  
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j  Male Sprague-Dawley rats; testing procedure: two response levers; pressing right lever 
resulted in the delivery drug solution for 6 s (fixed ratio [FR] 1 schedule). During injection, a 
stimulus light above active lever was illuminated, and light stayed illuminated throughout 
the time-outperiod (20 s) that followed each injection. Pressing the left lever had no 
programmed consequences, but the number of presses was counted. Daily test sessions 
lasted 2 h, and the experiment was continued for 7 consecutive days. Training: rats trained 
to press a lever to obtain 45 mg of food pellets until desired criteria had been achieved 
(100 food pellets over 3 consecutive days) in a 3 h daily session. Maximum training period 
was 7 days, and the successfully trained rats elected for further tests. 
 
 
5. Toxicology 
No information could be identified. 
 
6. Adverse Reactions in Humans 
Reports associated with the detection of DOC in biofluids taken from cases of intoxication 
is summarised in Table 3. The total number of cases reported in the scientific literature is 
small and the detection of other drugs has also been reported. Clinical features associated 
with DOC intoxication included agitation, aggressive behavior, hallucinations, tachycardia, 
rhabdomyolysis, seizures, and hyperthermia. In a report provided by the UNODC that 
includes data obtained from the UNODC’s ToxPortal, two post-mortem cases (one in 2015 
and one in 2018) have been described that feature the detection of DOC. One of those was 
described as a poly-drug case but details were not provided (39). 
 
 
 
Table 3. Case reports associated with the involvement of DOC a 
Year b Cases Patient, 
age 
Comments (examples) Reference 
Non-fatal intoxications  
2008 1 M, 20 Collapsed having tonic-clonic seizures at a rave party. At 
arrival at hospital: Glasgow Coma Scale of 3/15; sinus 
tachycardia with HR of 152 beats/min and BP of 144/57 
mmHg. T 36.8 °C; both pupils dilated (6 mm) and nonreactive 
to light; neurological examination normal, normal tone and 
reflexes and no evidence of clonus. Metabolic acidosis 
(thought to be linked to his tonic-clonic seizures before 
admission) and biochemical evidence of rhabdomyolysis. 
Patient admitted to ingestion of MDMA and what he believed 
was DOI.  
 
(40) 
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Serum and urine analysis revealed detection of DOC, MDMA 
(0.57 mg/L) and MDA (<0.05 mg/L). Blotters impregnated with 
DOC recovered from other attendees of rave. 
 
2014 2 M, 17 Medical attention needed 4 h after ingestion of a white 
powder believed to be DOC. One patient presented with 
generalised tonic-clonic seizure; on arrival at hospital HR 108; 
BP 131/54; T 38.5 °C; dilated pupils, agonal respirations, and a 
Glasgow Coma Score of 7 (E2M1V4); course complicated by 
agitation and hyperthermia requiring sedation, paralysis and 
external cooling, rhabdomyolysis and aspiration pneumonia. 
Extubated on day 2. 
 
Urine toxicology showed benzodiazepines and THC and DOC 
detected in urine and serum. 
 
Other patient described sense of euphoria and clarity and 
without complaints; pupils were 8 mm and reactive; BP 
152/89, HR 113, RR 28; afebrile. Endorsed ingesting ~2 mg; 
used 4 times in previous 2 weeks without adverse effects. 
 
(41) 
2015 1 M, 18 Man with history of migraines and a single febrile seizure at 
age 2 presented to the emergency department in status 
epilepticus; came home with agitation and hallucinations. 
Patient believed to have taken LSD and marijuana; patient 
found to be seizing with left gaze deviation, dilated pupils, and 
abnormal movements of all extremities. Tachycardia and 
tachypnea (BP 132/66, HR 125, T 37.3 °C, respiratory rate 24, 
oxygen saturation 95%); initial ECG showed sinus tachycardia 
with a prolonged QT interval (PR 176 milliseconds, QRS 94 
milliseconds, QTc 492 milliseconds). On arrival to hospital, still 
having tonic head turning and gaze deviation, with 
improvement in the tonic head movement with 2 mg of 
intravenous (i.v.) lorazepam. Initial laboratory test results 
notable for an anion gap metabolic lactic acidosis, profound 
leukocytosis, evidence of early rhabdomyolysis and 
hyperglycemia but otherwise normal electrolytes, and a 
negative troponin. Head computed tomography on arrival 
showed subtle hypodensities in the bilateral cerebellum and 
occipital lobes suggestive of posterior reversible 
encephalopathy syndrome. He was successfully extubated on 
hospital day 2 with amnesia for the event and mental status 
difficulties but an otherwise normal neurologic examination. 
 
(11) 
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Urine toxicology positive for benzodiazepines (treatment), 
opioids and cannabinoids. DOC serum concentration detected 
at 3 ng/mL approx. 5.5 h after ingestion.  
 
2015 6 M, 23–
27  
Six males presented at hospital 2 h after ingesting a drug 
different from their usual drug. All displayed a range of 
symptoms: severe agitation and extreme aggressive behavior 
(n = 6), delirium (n = 6), hallucinations (n = 6), mydriasis (n = 
6), tachycardia (n = 6) with a HR between 120 and 160 bpm 
and fever (n = 4) with a temperature between 38 and 39 °C. 
Four of them developed rhabdomyolysis. All discharged after 
12 to 72 hours.  
 
EMIT urine toxicology positive for amfetamine (n = 6), 
cannabis (n = 3) and opioids (n = 1). Urine analysis by GC-MS 
confirmed detection of DOC in all cases. 
 
(42) 
2016 1 M, NR c Patient presented with visual hallucinations, euphoria, altered 
mental status, tachycardia of HR = 128, T 38.1 °C. Four h into 
the visit (roughly 21 h after ingestion) still symptomatic 
(tachycardia and fever however resolved by then).  
 
Patient confirmed taking DOC blotter, which was confirmed in 
blood and urine; also positive for THC. Symptom duration 
reported to be 33 h. 
 
(43) 
2017 1 M, 18 Patient presented with seizures, agitation and hallucinations 
following the consumption of what was believed to be one 
LSD blotters and MDMA at rave party; incoherent speech, 
mydriasis; BP 130/50mmHg and HR 84. Poisoning severity 
score (PSS) calculated at 6 h after consumption was 2. Patient 
was discharged on the next day.  
 
Blood and urine samples obtained approx.. 6 h after ingestion. 
Plasma: DOC (10 μg/L), MDMA (190 μg/L), MDA (14 μg/L); 
urine: DOC (1300 μg/L), MDMA (50 μg/L), MDA (2.2 μg/L). LSD 
was not detected. 
 
(44) 
2017 1 M, 21 Patient presented with agitation and hallucinations following 
the consumption of what was believed to be 1.5 LSD blotters 
(same rave party, above); tachycardia (HR 135 beats/min), 
bilateral mydriasis, BP 133/74 mmHg. PSS = 2 at 8 h after 
ingestion.  
 
(44) 
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Blood and urine samples obtained approx. 8 h after ingestion. 
Plasma: DOC (13 μg/L); urine: DOC (720 μg/L), MDMA (0.05 
μg/L), MDA (0.02 μg/L); blood ethanol 0.13 g/L; LSD was not 
detected.  
 
2017 1 M, 21 Patient presented with agitation and hallucinations following 
the consumption of what was believed to be alcohol, 
ketamine, cocaine, cannabis and LSD during a rave party; 
visual hallucinations (at 24 h), BP 120/80mmHg, HR = 93 
beats/min. PSS = 2 at the 11 h time point. 
 
Blood and urine samples obtained approx..11 h after 
ingestion. Plasma: DOC (<10 μg/L), cocaine and 
benzoylecgonine (175 μg/L), methylecgonine (14 μg/L), 
ketamine (100 μg/L), norketamine (250 μg/L); urine: DOC (320 
μg/L), BECG (16.5 μg/L), MECG (4.9 μg/L), ketamine (9 μg/L), 
norketamine (7 μg/L); blood ethanol 1.28 g/L; cannabis 
positive, LSD was not detected. 
 
(44) 
2017 1 M, 16 Patient presented with “near death experience” and serious 
anxiety following consumption of two blotters; hallucinations 
and bilateral mydriasis with PSS = 2 at the 4 h point after 
consumption.  
 
Blood and urine samples obtained approx. 4 h after ingestion. 
Plasma: DOC (<10 μg/L); urine: DOC (300 μg/L), cannabis 
positive. 
 
(44) 
2017 1 M, 21 Patient presented with seizures following ingestion of “LSD 
derivative” bought on Internet; hyperthermia (39.5 °C), 
tachycardia (HR 150 beats/min), mydriasis, BP 150/80 mmHg, 
PSS = 3 at 5 h after ingestion. Management required 
intubation and ventilation.  
 
Blood and urine samples obtained approx. 5 h after ingestion. 
Plasma: DOC (18 μg/L), methiopropamine (430 μg/L), 
pentedrone (35 μg/L); urine: DOC (470 μg/L), 
methiopropamine (12.6 μg/L), pentedrone (1.12 μg/L), alpha-
methyltryptamine (0.5 μg/L), methadone (0.22 μg/L), free 
morphine (24 μg/L), codeine ( 5μg/L). 
 
(44) 
Fatal intoxications 
2014 1 M, 37 Known user of methamfetamine found dead at home and a 
collection of other new psychoactive substances found at the 
(9) 
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scene. Findings at autopsy included pulmonary edema and a 
subgaleal hemorrhage on the right parietal scalp.  
 
Quantitative analyses showed DOC at 377 ng/mL in iliac 
blood, 3,193 ng/mL in urine, 3,143 ng/g in liver and 683 ng/g 
in brain. DOC was not detected in the gastric contents of the 
decedent and no other drugs were detected. Cause of death 
ruled accidental due to DOC intoxication. 
 
a As of July 2019. 
b Refers to year published. 
c Age not reported. 
 
7. Dependence Potential 
A. Animal Studies 
Information could not be identified.  
 
B. Human Studies 
Information could not be identified.  
 
8. Abuse Potential 
A. Animal Studies 
Drug discrimination data (Table 2) indicate that DOC produces stimulus effects in rats 
similar to related serotonergic hallucinogens such as DOM, LSD and DMT when tested at 
two time points (peak depressant effect after 15 min and peak stimulant locomotor activity 
effects at 60 min mark) (36). This was consistent with previous observations where DOC 
was reported to show DOM-like stimulus effects in rats (32). One recent preliminary study 
suggested that DOC might show some reinforcing properties in rats under certain 
conditions (Table 2) and further studies are warranted to investigate this further. The rates 
of decline of lever pressing and their terminal levels maintained by DOC and vehicle were 
similar following their substitution for food, and DOC infusion nonspecifically increased the 
ratio of DOC to vehicle inactive lever pressing similarly to that on the active lever. 
Serotonergic hallucinogens are normally not known to be effective in initiating or 
maintaining self-administration (45) although some test subjects (rhesus monkeys) were 
observed to display a pattern of transient self-administration where DMT, mescaline and 
psilocybin (bot not DOI) was available (46).  
B. Human Studies 
No information could be identified. 
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9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of 
Medical Use 
DOC is not known to have any therapeutic applications. 
10. Listing on the WHO Model List of Essential Medicines 
DOC is not listed on the WHO Model List of Essential Medicines. 
11. Marketing Authorizations (as a Medicinal Product) 
DOC is not marketed as a medicinal product 
12. Industrial Use 
DOC has no reported industrial use. 
13. Non-Medical Use, Abuse and Dependence 
 
Household or subpopulation surveys that specifically probe for prevalence of DOC could 
not be identified in the currently available literature. Epidemiological data, such as 
prevalence of use, abuse and dependence information, are not available specifically for 
DOC. However, the Monitoring the Future (MTF), a national cross-sectional survey in the 
United States of America (USA) that queries use of hallucinogens and LSD in particular 
among high-school attending adolescents revealed that substance use remained relatively 
stable (47). The mode of use may involve the combinational use (intentionally or 
unintentionally) of other drugs and users may be unaware of the exact dose or compound 
being ingested (by whatever route). Dependence-producing properties in humans have not 
been studied but is unlikely to result in dependence similar to other serotonergic 
hallucinogens such as LSD or psilocybin. Although it is likely that some people who use 
hallucinogens such as LSD will also be likely to consider using closely related lysergamide-
based new psychoactive substances such as 1-propanoyl-LSD and perhaps also other 
phenylethylamine-based NPS (48, 49) it is unknown whether this would extend to 
hallucinogenic amfetamines such as DOC if users are given the choice. Use of DOC is 
presumably limited to recreational substance users and psychonauts rather than the 
general population. 
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and 
Dependence 
 
DOC is offered for sale by some Internet retailers as a substance in its own right which 
means that some users may be exposed intentionally whereas others may be exposed 
unintentionally after consuming a product with no indication that it contains this substance 
or following its ingestion as a component of other substances. Use of DOC is presumably 
limited to people who use hallucinogenic drugs in recreational settings (e.g. home 
environments, outdoors, discotheques/nightclubs and outdoor music festivals) rather than 
the general population. The information currently available suggests that DOC is most 
commonly found in the form of blotter papers and that it has also been misrepresented as 
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LSD (50, 51) (and Section 16). For example, the analysis of results obtained by a Spanish 
drug-testing organisation revealed that in the period January 2009 and February 2015, 41 
out of 18,222 tested samples (0.23%) contained DOC. Seventeen out of these 41 were 
handled (i.e. represented) as LSD (52). It is conceivable that DOC might be also 
supplied/sold as a “legal” replacement for LSD in countries that do not control this 
substance but further studies are needed to confirm this. Ingestion of DOC has been 
associated with a range of clinical features that will likely lead to impaired driving and 
potentially aggressive behaviour. The analysis of samples submitted for analysis by patients 
as part of the Swedish STRIDA project during the period 2010–2015 showed that one 
powdered sample identified as DOC was received in 2012 (53).  
15. Licit Production, Consumption and International Trade 
DOC is available as standard reference material and produced for scientific research by a 
number of commercial suppliers. Other uses could not be identified. 
16. Illicit Manufacture and Traffic and Related Information 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) received reports 
that DOC (identification notified in February 2004 but detected in the reporting country 
first in 2001) was encountered in seizures and collected specimens in Sweden, United 
Kingdom, France, Norway, Italy, Belgium, Ireland, Slovenia, Spain, Croatia, Denmark, Czech 
Republic, Luxembourg, and Latvia. The notifications were received between 2004–2016 
and the majority of notifications described the detection of DOC in blotters although 
powders and liquid samples were also reported (54). The Hungarian Institute for Forensic 
Sciences was cited to confirm confiscation of DOC (among other substances) during 2011–
2013 (55).  
 
In the period between 2006 and 2009, a number of DOC identifications obtained from 
seizures (mostly blotters but also some powdered and liquid material) have been published 
by the United States Drug Enforcement Administration (22, 23).  
 
Detections of DOC have also been reported to UNODC’s Early Warning Advisory on New 
Psychoactive Substances (56). Detections of DOC were reported by the following number 
of countries (period 2013-2016 contains multiple entries for some countries): 2009: 2; 
2010: 2; 2011: 2; 2012: 1; 2013: 41; 2014: 29; 2015: 40; 2016: 30; 2017: 17; 2018: 4. In a 
recent UNODC communication to the ECDD secretariat, the number of reporting countries 
stated was 77. UNODC’s evaluation of NPS emergence data (2015–2018) revealed the 
detection of 78 reports from a total number of 40 countries. Thirty-two reports in 2015; 
2016: 32; 2017: 3. Between 2015 and 2017, a total number of 8 countries reported the 
detection of DOC in blotter, tablet and what appeared to be powdered form (39). UNODC’s 
evaluation of seizure data (2015–2017) indicate that DOC was encountered in two 
countries in 2015 and 2017 (2015: “131 units” and “8 doses”; 2017: “1329 tablets” and 
“2.44 g”) (39). 
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17. Current International Controls and Their Impact 
DOC is not controlled under the 1961 (as amended by the 1972 Protocol), 1971 or 1988 
United Nation Conventions. 
18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on the 
Scheduling of the Substance 
No further comments. 
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances  
 
Refer to separate Annex 1: Report on WHO questionnaire for review of psychoactive substances 
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Annex 2: Investigations associated with the synthesis and chemical analysis 
of DOC (amongst other substances) including those reported in the 
published scientific literature 
 
 
Techniques a,b Comment Reference 
MP, EA, IR,  Synthesis of various analogues and pharmacological testing in 
rats 
(1) 
MP, EA Synthesis of various analogues (and DOC enantiomers) and 
pharmacological testing in animals 
(2) 
NMR, GC-MS Analysis of seized sample (3) 
NR Synthesis of various analogues (not reported for DOC) for 
receptor binding studies 
(4) 
NR Synthesis of various analogues for clinical studies (5) 
NR Synthesis of various analogues for receptor binding studies (6) 
NR Synthesis of various analogues for receptor binding studies (7) 
MP, EI-MS, NMR, IR, UV Synthesis and analytical characterisation (8) 
CE-ESI-MS Analysis of spiked urine samples (9) 
CE-DAD Analysis of rat blood following intraperitoneal administration (10) 
EI-, ESI-MS, UV, NMR Analysis of collected samples (11) 
GC-MS Metabolism study in rats and urine analysis (12) 
GC-MS, LC-MS In vitro metabolism studies and identification of cytochrome 
P450 isoenzymes 
(13) 
GC-MS Analysis of biological specimens (non-fatal intoxication) (14) 
GC-MS, LC-DAD Analysis of collected samples (15) 
GC-MS DOC included in drug panel for designer drug screen (16) 
LC-MECD Method development and analysis of collected samples (17) 
GC-(EI/CI)-MS, IR, NMR Analytical characterisation (18) 
IA, GC-MS Evaluation of cross-reactivity using immunoassays in urine 
specimens 
(19) 
LC-MS DOC included in analysis of spiked urine and application to 
clinical samples 
(20) 
CE Synthesis and chiral analysis using modified β-cyclodextrins (21) 
NR Synthesis of various [13C6]analogues (22, 23) 
LC-MS, IA Analysis of spiked biological specimens (24) 
IA Evaluation of cross-reactivity in spiked urine using 
immunoassays 
(25) 
GC-MS Analysis of biological specimens (fatal intoxication) (26) 
TLC, GC-MS Analysis of collected samples (27) 
LC-MS Analysis of biological specimens (non-fatal intoxication) (28) 
LC-MS Analysis of spiked urine and application to casework samples (29) 
IA Synthesis and evaluation of cross-reactivity in spiked urine 
using immunoassays 
(30) 
42nd ECDD (2019) Critical Review:  DOC (4-Chloro-2,5-dimethoxyamfetamine)     
 
 
 
Page 34 of 40 
IA Synthesis and evaluation of cross-reactivity in spiked oral fluid 
using immunoassays 
(31) 
MP, NMR, GC-MS, IR Analysis of reference material (32) 
LC-MS Analysis of biological specimens (non-fatal intoxication) (33) 
GC-MS Analysis of biological specimens (non-fatal intoxications) (34) 
LC-MS Analysis of spiked urine and application to casework samples (35) 
TLC, GC-MS Analysis of collected samples (36) 
GC-MS Analysis of biological specimens obtained from casework (37) 
GC-MS Included in analysis of blood samples obtained from casework  (38) 
GC-MS, IR Analysis of reference material (39) 
PSI-and ESI-MS Analysis of blotter samples (40) 
GC-MS Analysis of reference material (41) 
LC-MS Analysis of biological specimens (non-fatal intoxication) (42) 
IA Synthesis and evaluation of cross-reactivity in spiked blood, 
urine, and oral fluid using immunoassays 
(43) 
GC-MS Analysis of blotter papers (44) 
GC-MS, LC-DAD, LC-MS Analysis of biological specimens (non-fatal intoxications) (45) 
TLC, GC-MS Analysis of collected samples (46) 
LC-MS Analysis of spiked urine and application to clinical samples (47) 
LC-MS Analysis of collected samples and biological specimens 
obtained from clinical casework 
(48) 
NMR Analysis of collected samples (49) 
CE-DAD Chiral analysis of collected samples (50) 
LC-UV Chiral analysis of collected/seized/synthesised samples (51) 
LC-MS Analysis of biological specimens (fatal intoxication) (52) 
IMS, LC-MS Analysis of spiked oral fluid (53) 
a As of July 2019. 
 
b MP: melting point; EA: elemental analysis; IR: infrared spectroscopy; NMR: nuclear magnetic resonance 
spectroscopy; GC: gas chromatography; MS: mass spectrometry (may involve high or low resolution approaches); 
NR: details not reported; EI: electron ionisation; UV: ultraviolet spectroscopy; CE: capillary electrophoresis; ESI: 
electrospray ionisation; DAD: diode array detection; LC: liquid chromatography (various forms); MECD: multi-
channel electrochemical detection; CI: chemical ionisation; IA: immunoanalysis; TLC: thin-layer chromatography; 
PSI: paper spray ionisation; IMS: ion mobility spectrometry. 
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